Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2018

Open Access 01-08-2018 | Review

Natural History of Barrett’s Esophagus

Authors: Ernst J. Kuipers, Manon C. Spaander

Published in: Digestive Diseases and Sciences | Issue 8/2018

Login to get access

Abstract

Barrett’s esophagus (BE) is a very common condition. We have obtained fairly profound knowledge of the natural history of this condition. This results from many cross-sectional and cohort studies, many describing patients undergoing long-term surveillance. Their consent to use their clinical data has improved our knowledge to the benefit of these same and other patients. The prevalence of BE increases with age both in men and in women. This increase starts at a younger age in men than in women. The incidence of high-grade dysplasia and cancer in BE depends on segment length, gender, and age. The latter two likely indicate the duration of the presence of BE in an individual patient. Other factors that influence the incidence of dysplasia and cancer are smoking behavior and use of certain medications such as PPIs, statins, and NSAIDs. Surveillance of BE and treatment of dysplasia can impact the incidence of and mortality due to esophageal adenocarcinoma. This is of major benefit to a subgroup of BE patients. The epidemiology and burden of disease ask for further efforts to develop targeted screening, surveillance, and intervention techniques in coming years.
Literature
1.
go back to reference Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143:1179.e3–1187.e3.CrossRef Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143:1179.e3–1187.e3.CrossRef
2.
go back to reference El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871–880.CrossRefPubMed El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871–880.CrossRefPubMed
3.
4.
go back to reference van Blankenstein M, Looman CWN, Johnston BJ, et al. Age and sex distribution of the prevalence of Barrett’s esophagus found in a primary referral endoscopy center. Am J Gastroenterol. 2005;100:568–576.CrossRefPubMed van Blankenstein M, Looman CWN, Johnston BJ, et al. Age and sex distribution of the prevalence of Barrett’s esophagus found in a primary referral endoscopy center. Am J Gastroenterol. 2005;100:568–576.CrossRefPubMed
5.
6.
go back to reference Verbeek RE, Spittuler LF, Peute A, et al. Familial clustering of Barrett’s esophagus and esophageal adenocarcinoma in a European cohort. Clin Gastroenterol Hepatol. 2014;12:1656.e1–1663.e1.CrossRef Verbeek RE, Spittuler LF, Peute A, et al. Familial clustering of Barrett’s esophagus and esophageal adenocarcinoma in a European cohort. Clin Gastroenterol Hepatol. 2014;12:1656.e1–1663.e1.CrossRef
7.
go back to reference Gharahkhani P, Fitzgerald RC, Vaughan TL, et al. Genome-wide association studies in oesophageal adenocarcinoma and Barrett’s oesophagus: a large-scale meta-analysis. Lancet Oncol. 2016;17:1363–1373.CrossRefPubMedPubMedCentral Gharahkhani P, Fitzgerald RC, Vaughan TL, et al. Genome-wide association studies in oesophageal adenocarcinoma and Barrett’s oesophagus: a large-scale meta-analysis. Lancet Oncol. 2016;17:1363–1373.CrossRefPubMedPubMedCentral
8.
go back to reference Palles C, Chegwidden L, Li X, et al. Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett’s esophagus. Gastroenterology. 2015;148:367–378.CrossRefPubMedPubMedCentral Palles C, Chegwidden L, Li X, et al. Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett’s esophagus. Gastroenterology. 2015;148:367–378.CrossRefPubMedPubMedCentral
9.
go back to reference Sun X, Elston RC, Barnholtz-Sloan JS, et al. Predicting Barrett’s esophagus in families: an esophagus translational research network (BETRNet) model fitting clinical data to a familial paradigm. Cancer Epidemiol Biomarkers Prev. 2016;25:727–735.CrossRefPubMedPubMedCentral Sun X, Elston RC, Barnholtz-Sloan JS, et al. Predicting Barrett’s esophagus in families: an esophagus translational research network (BETRNet) model fitting clinical data to a familial paradigm. Cancer Epidemiol Biomarkers Prev. 2016;25:727–735.CrossRefPubMedPubMedCentral
10.
go back to reference Dong J, Buas MF, Gharahkhani P, et al. Determining risk of Barrett’s esophagus and esophageal adenocarcinoma based on epidemiologic factors and genetic variants. Gastroenterology. 2018;154:1273–1281.CrossRefPubMed Dong J, Buas MF, Gharahkhani P, et al. Determining risk of Barrett’s esophagus and esophageal adenocarcinoma based on epidemiologic factors and genetic variants. Gastroenterology. 2018;154:1273–1281.CrossRefPubMed
11.
go back to reference Fock KM, Talley N, Goh KL, et al. Asia–Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett’s oesophagus. Gut. 2016;65:1402–1415.CrossRefPubMed Fock KM, Talley N, Goh KL, et al. Asia–Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett’s oesophagus. Gut. 2016;65:1402–1415.CrossRefPubMed
12.
go back to reference Cameron AJ, Zinsmeister AR, Ballard DJ, et al. Prevalence of columnar-lined (Barrett’s) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology. 1990;99:918–922.CrossRefPubMed Cameron AJ, Zinsmeister AR, Ballard DJ, et al. Prevalence of columnar-lined (Barrett’s) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology. 1990;99:918–922.CrossRefPubMed
13.
14.
go back to reference Masclee GMC, Coloma PM, de Wilde M, et al. The incidence of Barrett’s oesophagus and oesophageal adenocarcinoma in the United Kingdom and the Netherlands is levelling off. Aliment Pharmacol Ther. 2014;39:1321–1330.CrossRefPubMed Masclee GMC, Coloma PM, de Wilde M, et al. The incidence of Barrett’s oesophagus and oesophageal adenocarcinoma in the United Kingdom and the Netherlands is levelling off. Aliment Pharmacol Ther. 2014;39:1321–1330.CrossRefPubMed
15.
go back to reference Shiota S, Singh S, Anshasi A, et al. Prevalence of Barrett’s esophagus in Asian countries: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13:1907–1918.CrossRefPubMedPubMedCentral Shiota S, Singh S, Anshasi A, et al. Prevalence of Barrett’s esophagus in Asian countries: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13:1907–1918.CrossRefPubMedPubMedCentral
16.
go back to reference Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–1677.CrossRefPubMed Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–1677.CrossRefPubMed
17.
go back to reference Ward EM, Wolfsen HC, Achem SR, et al. Barrett’s esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol. 2006;101:12–17.CrossRefPubMed Ward EM, Wolfsen HC, Achem SR, et al. Barrett’s esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol. 2006;101:12–17.CrossRefPubMed
18.
go back to reference Zagari RM, Eusebi LH, Rabitti S, et al. Prevalence of upper gastrointestinal endoscopic findings in the community: a systematic review of studies in unselected samples of subjects. J Gastroenterol Hepatol. 2016;31:1527–1538.CrossRefPubMed Zagari RM, Eusebi LH, Rabitti S, et al. Prevalence of upper gastrointestinal endoscopic findings in the community: a systematic review of studies in unselected samples of subjects. J Gastroenterol Hepatol. 2016;31:1527–1538.CrossRefPubMed
19.
go back to reference Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–1831.CrossRefPubMed Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–1831.CrossRefPubMed
20.
go back to reference Zagari RM, Fuccio L, Wallander M-A, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano–Monghidoro study. Gut. 2008;57:1354–1359.CrossRefPubMed Zagari RM, Fuccio L, Wallander M-A, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano–Monghidoro study. Gut. 2008;57:1354–1359.CrossRefPubMed
21.
go back to reference Zou D, He J, Ma X, et al. Epidemiology of symptom-defined gastroesophageal reflux disease and reflux esophagitis: the systematic investigation of gastrointestinal diseases in China (SILC). Scand J Gastroenterol. 2011;46:133–141.CrossRefPubMed Zou D, He J, Ma X, et al. Epidemiology of symptom-defined gastroesophageal reflux disease and reflux esophagitis: the systematic investigation of gastrointestinal diseases in China (SILC). Scand J Gastroenterol. 2011;46:133–141.CrossRefPubMed
22.
go back to reference van Soest EM, Siersema PD, Dieleman JP, et al. Age and sex distribution of the incidence of Barrett’s esophagus found in a Dutch primary care population. Am J Gastroenterol. 2005;100:2599–2600.CrossRefPubMed van Soest EM, Siersema PD, Dieleman JP, et al. Age and sex distribution of the incidence of Barrett’s esophagus found in a Dutch primary care population. Am J Gastroenterol. 2005;100:2599–2600.CrossRefPubMed
23.
go back to reference Coleman HG, Bhat S, Murray LJ, et al. Increasing incidence of Barrett’s oesophagus: a population-based study. Eur J Epidemiol. 2011;26:739–745.CrossRefPubMed Coleman HG, Bhat S, Murray LJ, et al. Increasing incidence of Barrett’s oesophagus: a population-based study. Eur J Epidemiol. 2011;26:739–745.CrossRefPubMed
24.
go back to reference den Hoed CM, van Blankenstein M, Dees J, et al. The minimal incubation period from the onset of Barrett’s oesophagus to symptomatic adenocarcinoma. Br J Cancer. 2011;105:200–205.CrossRef den Hoed CM, van Blankenstein M, Dees J, et al. The minimal incubation period from the onset of Barrett’s oesophagus to symptomatic adenocarcinoma. Br J Cancer. 2011;105:200–205.CrossRef
25.
go back to reference Thomas T, Abrams KR, De Caestecker JS, et al. Meta analysis: cancer risk in Barrett’s oesophagus. Aliment Pharmacol Ther. 2007;26:1465–1477.CrossRefPubMed Thomas T, Abrams KR, De Caestecker JS, et al. Meta analysis: cancer risk in Barrett’s oesophagus. Aliment Pharmacol Ther. 2007;26:1465–1477.CrossRefPubMed
26.
go back to reference Yousef F, Cardwell C, Cantwell MM, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:237–249.CrossRefPubMed Yousef F, Cardwell C, Cantwell MM, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:237–249.CrossRefPubMed
27.
go back to reference Sikkema M, de Jonge PJF, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:235–244.CrossRefPubMed Sikkema M, de Jonge PJF, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:235–244.CrossRefPubMed
28.
go back to reference Qiao Y, Hyder A, Bae SJ, et al. Surveillance in patients with Barrett’s esophagus for early detection of esophageal adenocarcinoma: a systematic review and meta-analysis. Clin Transl Gastroenterol. 2015;6:e131.CrossRefPubMedPubMedCentral Qiao Y, Hyder A, Bae SJ, et al. Surveillance in patients with Barrett’s esophagus for early detection of esophageal adenocarcinoma: a systematic review and meta-analysis. Clin Transl Gastroenterol. 2015;6:e131.CrossRefPubMedPubMedCentral
29.
go back to reference Qumseya BJ, Wani S, Gendy S, et al. Disease progression in Barrett’s low-grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta-analysis. Am J Gastroenterol. 2017;112:849–865.CrossRefPubMed Qumseya BJ, Wani S, Gendy S, et al. Disease progression in Barrett’s low-grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta-analysis. Am J Gastroenterol. 2017;112:849–865.CrossRefPubMed
30.
go back to reference Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61:970–976.CrossRefPubMed Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61:970–976.CrossRefPubMed
31.
go back to reference Thota PN, Vennalaganti P, Vennelaganti S, et al. Low risk of high-grade dysplasia or esophageal adenocarcinoma among patients With Barrett’s esophagus less than 1 cm (irregular Z line) within 5 years of index endoscopy. Gastroenterology. 2017;152:987–992.CrossRefPubMed Thota PN, Vennalaganti P, Vennelaganti S, et al. Low risk of high-grade dysplasia or esophageal adenocarcinoma among patients With Barrett’s esophagus less than 1 cm (irregular Z line) within 5 years of index endoscopy. Gastroenterology. 2017;152:987–992.CrossRefPubMed
32.
go back to reference Singh S, Manickam P, Amin AV, et al. Incidence of esophageal adenocarcinoma in Barrett’s esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79:897.e4–909.e4. Singh S, Manickam P, Amin AV, et al. Incidence of esophageal adenocarcinoma in Barrett’s esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79:897.e4–909.e4.
33.
go back to reference Kestens C, Offerhaus GJA, van Baal JWPM, et al. Patients with Barrett’s esophagus and persistent low-grade dysplasia have an increased risk for high-grade dysplasia and cancer. Clin Gastroenterol Hepatol. 2016;14:956.e1–962.e1.CrossRef Kestens C, Offerhaus GJA, van Baal JWPM, et al. Patients with Barrett’s esophagus and persistent low-grade dysplasia have an increased risk for high-grade dysplasia and cancer. Clin Gastroenterol Hepatol. 2016;14:956.e1–962.e1.CrossRef
34.
go back to reference Phoa KN, van Vilsteren FGI, Weusten BLAM, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311:1209–1217.CrossRefPubMed Phoa KN, van Vilsteren FGI, Weusten BLAM, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311:1209–1217.CrossRefPubMed
35.
go back to reference Rastogi A, Puli S, El-Serag HB, et al. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67:394–398.CrossRefPubMed Rastogi A, Puli S, El-Serag HB, et al. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67:394–398.CrossRefPubMed
36.
go back to reference Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, Based on a Delphi process. Gastroenterology. 2012;143:336–346.CrossRefPubMedPubMedCentral Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, Based on a Delphi process. Gastroenterology. 2012;143:336–346.CrossRefPubMedPubMedCentral
37.
go back to reference Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRefPubMed Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRefPubMed
38.
go back to reference Shaheen NJ, Falk GW, Iyer PG, et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50.CrossRefPubMed Shaheen NJ, Falk GW, Iyer PG, et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50.CrossRefPubMed
39.
go back to reference Anaparthy R, Gaddam S, Kanakadandi V, et al. Association between length of Barrett’s esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol. 2013;11:1430–1436.CrossRefPubMed Anaparthy R, Gaddam S, Kanakadandi V, et al. Association between length of Barrett’s esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol. 2013;11:1430–1436.CrossRefPubMed
40.
go back to reference Sikkema M, Looman CWN, Steyerberg EW, et al. Predictors for neoplastic progression in patients with Barrett’s esophagus: a prospective cohort study. Am J Gastroenterol. 2011;106:1231–1238.CrossRefPubMed Sikkema M, Looman CWN, Steyerberg EW, et al. Predictors for neoplastic progression in patients with Barrett’s esophagus: a prospective cohort study. Am J Gastroenterol. 2011;106:1231–1238.CrossRefPubMed
41.
go back to reference Kastelein F, Spaander MCW, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2013;11:382–388.CrossRefPubMed Kastelein F, Spaander MCW, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2013;11:382–388.CrossRefPubMed
42.
go back to reference Singh S, Garg SK, Singh PP, et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014;63:1229–1237.CrossRefPubMed Singh S, Garg SK, Singh PP, et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014;63:1229–1237.CrossRefPubMed
43.
go back to reference Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology. 2010;138:2260–2266.CrossRefPubMedPubMedCentral Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology. 2010;138:2260–2266.CrossRefPubMedPubMedCentral
44.
go back to reference Kastelein F, Spaander MCW, Biermann K, et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett’s esophagus. Gastroenterology. 2011;141:2000–2008.CrossRefPubMed Kastelein F, Spaander MCW, Biermann K, et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett’s esophagus. Gastroenterology. 2011;141:2000–2008.CrossRefPubMed
45.
go back to reference Nguyen T, Duan Z, Naik AD, et al. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett’s esophagus: a nested case-control study. Gastroenterology. 2015;149:1392–1398.CrossRefPubMed Nguyen T, Duan Z, Naik AD, et al. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett’s esophagus: a nested case-control study. Gastroenterology. 2015;149:1392–1398.CrossRefPubMed
46.
go back to reference Coleman HG, Bhat S, Johnston BT, et al. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett’s esophagus. Gastroenterology. 2012;142:233–240.CrossRefPubMed Coleman HG, Bhat S, Johnston BT, et al. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett’s esophagus. Gastroenterology. 2012;142:233–240.CrossRefPubMed
47.
go back to reference Krishnamoorthi R, Singh S, Ragunathan K, et al. Factors associated with progression of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017. Krishnamoorthi R, Singh S, Ragunathan K, et al. Factors associated with progression of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017.
48.
go back to reference Derakhshan MH, Liptrot S, Paul J, et al. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut. 2009;58:16–23.CrossRefPubMed Derakhshan MH, Liptrot S, Paul J, et al. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut. 2009;58:16–23.CrossRefPubMed
49.
go back to reference Bhat SK, McManus DT, Coleman HG, et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett’s oesophagus: a population-based study. Gut. 2015;64:20–25.CrossRefPubMed Bhat SK, McManus DT, Coleman HG, et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett’s oesophagus: a population-based study. Gut. 2015;64:20–25.CrossRefPubMed
50.
go back to reference de Jonge PJF, van Blankenstein M, Looman CWN, et al. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. 2010;59:1030–1036.CrossRefPubMed de Jonge PJF, van Blankenstein M, Looman CWN, et al. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. 2010;59:1030–1036.CrossRefPubMed
51.
go back to reference Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–1057.CrossRefPubMedPubMedCentral Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–1057.CrossRefPubMedPubMedCentral
52.
go back to reference Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–1383.CrossRefPubMed Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–1383.CrossRefPubMed
53.
go back to reference Kastelein F, van Olphen S, Steyerberg EW, et al. Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness analysis. Gut. 2015;64:864–871.CrossRefPubMed Kastelein F, van Olphen S, Steyerberg EW, et al. Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness analysis. Gut. 2015;64:864–871.CrossRefPubMed
54.
go back to reference Gordon LG, Mayne GC, Hirst NG, et al. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest Endosc. 2014;79:242.e6–256.e6.CrossRef Gordon LG, Mayne GC, Hirst NG, et al. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest Endosc. 2014;79:242.e6–256.e6.CrossRef
55.
go back to reference Benaglia T, Sharples LD, Fitzgerald RC, et al. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett’s esophagus. Gastroenterology. 2013;144:62.e6–73.e6.CrossRef Benaglia T, Sharples LD, Fitzgerald RC, et al. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett’s esophagus. Gastroenterology. 2013;144:62.e6–73.e6.CrossRef
56.
go back to reference Inadomi JM. Cost considerations in implementing a screening and surveillance strategy for Barrett’s oesophagus. Best Pract Res Clin Gastroenterol. 2015;29:51–63.CrossRefPubMed Inadomi JM. Cost considerations in implementing a screening and surveillance strategy for Barrett’s oesophagus. Best Pract Res Clin Gastroenterol. 2015;29:51–63.CrossRefPubMed
57.
go back to reference Karagiannis-Voules DA, Biedermann P, Ekpo UF, et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2014;385:117–171. Karagiannis-Voules DA, Biedermann P, Ekpo UF, et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2014;385:117–171.
59.
go back to reference van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–2084.CrossRefPubMed van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–2084.CrossRefPubMed
60.
go back to reference Noordman BJ, Shapiro J, Spaander MC, et al. Accuracy of detecting residual disease after cross neoadjuvant chemoradiotherapy for esophageal cancer (preSANO Trial): rationale and protocol. JMIR Res Protoc. 2015;4:e79.CrossRefPubMedPubMedCentral Noordman BJ, Shapiro J, Spaander MC, et al. Accuracy of detecting residual disease after cross neoadjuvant chemoradiotherapy for esophageal cancer (preSANO Trial): rationale and protocol. JMIR Res Protoc. 2015;4:e79.CrossRefPubMedPubMedCentral
61.
go back to reference de Jonge PJF, van Blankenstein M, Grady WM, et al. Barrett’s oesophagus: epidemiology, cancer risk and implications for management. Gut. 2014;63:191–202.CrossRefPubMed de Jonge PJF, van Blankenstein M, Grady WM, et al. Barrett’s oesophagus: epidemiology, cancer risk and implications for management. Gut. 2014;63:191–202.CrossRefPubMed
62.
go back to reference Parasa S, Vennalaganti S, Gaddam S, et al. Development and validation of a model to determine risk of progression of Barrett’s esophagus to neoplasia. Gastroenterology. 2018;154:1282–1289.CrossRefPubMed Parasa S, Vennalaganti S, Gaddam S, et al. Development and validation of a model to determine risk of progression of Barrett’s esophagus to neoplasia. Gastroenterology. 2018;154:1282–1289.CrossRefPubMed
Metadata
Title
Natural History of Barrett’s Esophagus
Authors
Ernst J. Kuipers
Manon C. Spaander
Publication date
01-08-2018
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2018
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5161-x

Other articles of this Issue 8/2018

Digestive Diseases and Sciences 8/2018 Go to the issue